+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Supportive Care - Global Market Trajectory & Analytics

  • ID: 5139745
  • Report
  • April 2021
  • Region: Global
  • 140 pages
  • Global Industry Analysts, Inc
Global Cancer Supportive Care Market to Reach $24.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Cancer Supportive Care estimated at US$21.7 Billion in the year 2020, is projected to reach a revised size of US$24.6 Billion by 2027, growing at a CAGR of 1.8% over the analysis period 2020-2027. G-CSFs, one of the segments analyzed in the report, is projected to record a 1.3% CAGR and reach US$5.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bisphosphonates segment is readjusted to a revised 2.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $6.4 Billion, While China is Forecast to Grow at 1.5% CAGR

The Cancer Supportive Care market in the U.S. is estimated at US$6.4 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2027 trailing a CAGR of 1.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 1.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Antiemetics Segment to Record 2.4% CAGR

In the global Antiemetics segment, USA, Canada, Japan, China and Europe will drive the 2.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.8 Billion by the year 2027.

Select Competitors (Total 44 Featured):
  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Tesaro, Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Cancer Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for G-CSFs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for G-CSFs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 19: World Current & Future Analysis for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World Historic Review for ESAs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: World 15-Year Perspective for ESAs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 22: USA Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: USA Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: USA 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Canada 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 28: Japan Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: Japan Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: Japan 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 31: China Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: China Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: China 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 34: Europe Current & Future Analysis for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 35: Europe Historic Review for Cancer Supportive Care by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Europe 15-Year Perspective for Cancer Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 37: Europe Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: Europe Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 40: France Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: France Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: France 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 43: Germany Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Germany Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Germany 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 46: Italy Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: Italy Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: Italy 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 49: UK Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: UK Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: UK 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 52: Rest of Europe Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Rest of Europe Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Rest of Europe 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 55: Asia-Pacific Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Asia-Pacific Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Asia-Pacific 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
  • Table 58: Rest of World Current & Future Analysis for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 59: Rest of World Historic Review for Cancer Supportive Care by Therapeutic Class - G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 60: Rest of World 15-Year Perspective for Cancer Supportive Care by Therapeutic Class - Percentage Breakdown of Value Sales for G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs and ESAs for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 44
Note: Product cover images may vary from those shown
Adroll
adroll